These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38789494)

  • 1. A new mechanism of thyroid hormone receptor β agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles.
    Sun K; Zhu NL; Huang SL; Qu H; Gu YP; Qin L; Liu J; Leng Y
    Acta Pharmacol Sin; 2024 Oct; 45(10):2134-2148. PubMed ID: 38789494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD.
    Caddeo A; Kowalik MA; Serra M; Runfola M; Bacci A; Rapposelli S; Columbano A; Perra A
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
    Luong XG; Stevens SK; Jekle A; Lin TI; Gupta K; Misner D; Chanda S; Mukherjee S; Williams C; Stoycheva A; Blatt LM; Beigelman LN; Symons JA; Raboisson P; McGowan D; Vandyck K; Deval J
    PLoS One; 2020; 15(12):e0240338. PubMed ID: 33306682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Dutta D; Kamrul-Hasan ABM; Mondal E; Nagendra L; Joshi A; Bhattacharya S
    Endocr Pract; 2024 Jul; 30(7):631-638. PubMed ID: 38697306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resmetirom: First Approval.
    Keam SJ
    Drugs; 2024 Jun; 84(6):729-735. PubMed ID: 38771485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis.
    Yang C; Wan M; Xu D; Pan D; Xia H; Yang L; Sun G
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soyasaponin A
    Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
    Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
    Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH.
    Hernandez GV; Smith VA; Melnyk M; Burd MA; Sprayberry KA; Edwards MS; Peterson DG; Bennet DC; Fanter RK; Columbus DA; Steibel JP; Glanz H; Immoos C; Rice MS; Santiago-Rodriguez TM; Blank J; VanderKelen JJ; Kitts CL; Piccolo BD; La Frano MR; Burrin DG; Maj M; Manjarin R
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G582-G609. PubMed ID: 32003601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated serum metabolomics, 16S rRNA sequencing and bile acid profiling to reveal the potential mechanism of gentiopicroside against nonalcoholic steatohepatitis in lean mice.
    Li Z; Zhu X; Li C; Tang R; Zou Y; Liu S
    J Ethnopharmacol; 2024 Nov; 334():118526. PubMed ID: 38972531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.
    Rao A; Kosters A; Mells JE; Zhang W; Setchell KD; Amanso AM; Wynn GM; Xu T; Keller BT; Yin H; Banton S; Jones DP; Wu H; Dawson PA; Karpen SJ
    Sci Transl Med; 2016 Sep; 8(357):357ra122. PubMed ID: 27655848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
    N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p; Zhang L-f; Liu S; Hua H; Zhang L; Liu B-c; Wang R-r
    Microbiol Spectr; 2024 Jun; 12(6):e0197923. PubMed ID: 38647315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis.
    Xie G; Jiang R; Wang X; Liu P; Zhao A; Wu Y; Huang F; Liu Z; Rajani C; Zheng X; Qiu J; Zhang X; Zhao S; Bian H; Gao X; Sun B; Jia W
    EBioMedicine; 2021 Apr; 66():103290. PubMed ID: 33752128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora.
    Miao X; Luo P; Liu J; Wang J; Chen Y
    Lipids Health Dis; 2023 Aug; 22(1):112. PubMed ID: 37533083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice.
    Zheng N; Wang H; Zhu W; Li Y; Li H
    J Ethnopharmacol; 2024 Feb; 320():117401. PubMed ID: 37967775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.